Jul 2026· Biochemistry and Biophysics Reports· Vol 47, pp. 102720· 0 citations· 32 references
Medicine
TL;DR
A computational proof of concept for the design of dual-target DNA tweezer nanostructures is provided and a foundation for future development and experimental evaluation of DNA-based biosensing platforms for glioblastoma-associated biomarkers is established.
Abstract
Glioblastoma multiforme (GBM) is among the most aggressive malignant brain tumors and is characterized by severe infiltration into surrounding brain tissue, rendering early detection exceedingly difficult with current diagnostic imaging methods. Chosen biomarkers S100A4, with a role in cell motility and tumor metastasis, and midkine (MDK), connected to tumor microenvironment remodeling and expansion, are both linked to GBM's infiltrative proliferation. This study investigates a computational framework for the structure-guided design of DNA tweezer nanostructures, evaluated for predicted interactions with S100A4 and MDK. AlphaFold 3 modeling predicted the three-dimensional structures of eight three-stranded, hinge-scaffolded DNA tweezer candidates. DNA structures and target proteins were paired together in molecular docking simulations conducted with HDOCK, from which docking analyses predicted favorable binding arrangements of the complexes identified. Among the constructs investigated, DT3_8 exhibited the most favorable predicted interaction profile across the integrated computational analyses. Comparative docking against additional S100 family proteins with similar electrostatic characteristics further suggested that the predicted interaction profile of DT3_8 may not be explained solely by nonspecific electrostatic complementarity. Collectively, these findings provide a computational proof of concept for the design of dual-target DNA tweezer nanostructures and establish a foundation for future development and experimental evaluation of DNA-based biosensing platforms for glioblastoma-associated biomarkers.
G856-6814 is supported as a NAT10-targeting inhibitory scaffold that requires broader selectivity and in vivo evaluation and attenuation of cellular effects after NAT10 knockdown.
Chao Xu, Shi-Lei Zhao, Bing Xu et al.· Journal of Computer-Aided Mo...· 0 citations
I1Hit1 and I2Hit1 are highlighted as novel therapeutic compounds with efficient IDH-target inhibition to address epigenetic modification in GBM, and further experimental validation of these compounds is required to demonstrate potential inhibitors of IDH-driven metabolism in GBM.
Nivedhitha Tamilazhagan, S. Arumugam· Frontiers in Bioinformatics· 0 citations
Findings validate the diphenylpyrazine scaffold as a promising chemotype for Skp2–Cks1 inhibition and identify C3 as a strong lead for further optimization.
Emadeldin M. Kamel, A. A. Allam, H. Rudayni et al.· Journal of Computer-Aided Mo...· 0 citations
Cyclin-dependent kinase 6 (CDK6) contributes to G1-to-S cell-cycle progression and represents an established therapeutic target in hormone receptor-positive breast cancer. However, adverse effects and acquired resistance associated with current CDK4/6 inhibitors support continued investigation of alternative chemical s...
Syarifuddin Husain, Ruzianisra Mohamed, Khairul Bariyyah Abd. Halim et al.· Journal of Molecular Graphic...· 0 citations
Background Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide, necessitating the development of safer and more targeted therapeutic strategies. This study computationally extends our previous experimental investigation of a peptide derived from Lacticaseibacillus casei by...
G. R. Shree Kumari, M. Vaithilingam· Frontiers in Bioinformatics· 0 citations
Aptamers are versatile single-stranded nucleic acids with high specificity and stability, making them ideal for targeting challenging biomolecules. Their structural flexibility enables selective recognition of nonprotein targets such as microRNAs (miRNAs). Among these, miR-10b plays a pivotal role in cancer progression...
K. Mokgopa, Kevin A. Lobb, T. Tshiwawa· ACS Omega· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.